Full Archive

It all depends

Success is sometimes a subjective test unlike a math problem which typically yields an answer when completed. This past Sunday my Bears lost to the Dolphins on the scoreboard, but our quarterback had a successful day. This is the difference between a math problem, the score, and a subjective success Mr. Fields performance. This by the way is in sharp contrast to a certain quarterback who has now lost five...

It’s a very wacky world

It’s appropriate with November being diabetes month that wackiness is reaching new heights so let’s get right to it Say Goodbye to Glysens who will be officially closing their doors next week. It’s been a long run but frankly we aren’t all that surprised not because the technology is bad but as we have seen with Senseonics (who just might be next) there isn’t much of a demand for an implantable...

Up is better

There are times when you sit and wonder just what people are thinking. Yesterday the Tandem story was all about their downward revision to guidance and the reasons for this downward revision. Today the story with Insulet who reported this afternoon is the same only in the opposite direction as they revised guidance upward and as expected the street is responding positively with shares now up over 10% in after-hours...

Rough Waters Ahead

What jumps out from the earnings announcement from Tandem are these items “In this highly variable environment, we are factoring greater caution into our guidance to re-baseline expectations for the next few quarters,” said Leigh Vosseller, executive vice president and chief financial officer. “The timing of our potential new product introductions next year adds increased complexity to the current market dynamics, so we feel it’s prudent for our guidance to reflect...

Is this a supply chain battle?

As anticipated the results from Novo Nordisk were driven by Ozempic and Wegovy. Insulin continues to be drag on results but that too was expected. So just as they battled it out over insulin Novo and Lilly are now battling for supremacy in the GLP-1 ring. The irony here is this battle could ultimately be decided by who has the better supply chain and manufacturing capabilities. The reality here is both...

Fattening the bottom line

Not like we needed more evidence, but the results released this morning by Lilly just confirm what we already knew Mounjaro is off to a strong start and well on its way to becoming a mega blockbuster. The FDA granted the drug a fast-track designation for obesity which will set up another bout with their rival Novo Nordisk who reports tomorrow. While it’s early in the Mounjaro launch here are...

So, has anything changed?

Now that Abbott and Dexcom have reported results has anything changed? The simple answer is no they continue to own the CGM space and will do so for the foreseeable future as competition is no existent. Reimbursement conditions continue to improve, there is still plenty of room to grow in the diabetes sector and the non-diabetic sector is growing more rapidly than anticipated. While everyone else continues to view this...